JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis.

Renal fibrosis is a final common manifestation of CKD resulting in progressive loss of kidney function. Bone marrow-derived fibroblast precursors contribute significantly to the pathogenesis of renal fibrosis. However, the signaling mechanisms underlying the activation of bone marrow-derived fibroblast precursors in the kidney are not fully understood. In this study, we investigated the role of the Janus kinase 3 (JAK3)/signal transducer and activator of transcription (STAT6) signaling pathway in the activation of bone marrow-derived fibroblasts. In cultured mouse monocytes, IL-4 or IL-13 activated STAT6 and induced expression of α-smooth muscle actin and extracellular matrix proteins (fibronectin and collagen I), which was abolished by a JAK3 inhibitor (CP690,550) in a dose-dependent manner or blocked in the absence of STAT6. In vivo, STAT6 was activated in interstitial cells of the obstructed kidney, an effect that was abolished by CP690,550. Mice treated with CP690,550 accumulated fewer bone marrow-derived fibroblasts in the obstructed kidneys compared with vehicle-treated mice. Treatment with CP690,550 also significantly reduced myofibroblast transformation, matrix protein expression, fibrosis development, and apoptosis in obstructed kidneys. Furthermore, STAT6-deficient mice accumulated fewer bone marrow-derived fibroblasts in the obstructed kidneys, produced less extracellular matrix protein, and developed much less fibrosis. Finally, wild-type mice engrafted with STAT6(-/-) bone marrow cells displayed fewer bone marrow-derived fibroblasts in the obstructed kidneys and showed less severe renal fibrosis compared with wild-type mice engrafted with STAT6(+/+) bone marrow cells. Our results demonstrate that JAK3/STAT6 has an important role in bone marrow-derived fibroblast activation, extracellular matrix production, and interstitial fibrosis development.

[1]  S. Gordon,et al.  Macrophage heterogeneity in tissues: phenotypic diversity and functions , 2014, Immunological reviews.

[2]  M. Entman,et al.  CXCR6 Plays a Critical Role in Angiotensin II–Induced Renal Injury and Fibrosis , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Entman,et al.  The chemokine receptor CXCR6 contributes to recruitment of bone marrow-derived fibroblast precursors in renal fibrosis , 2014, Kidney international.

[4]  Xin-Hua Feng,et al.  Smad3 Signaling Activates Bone Marrow-Derived Fibroblasts in Renal Fibrosis , 2014, Laboratory Investigation.

[5]  A. Menter,et al.  Tofacitinib (CP‐690,550), an oral Janus kinase inhibitor, improves patient‐reported outcomes in a phase 2b, randomized, double‐blind, placebo‐controlled study in patients with moderate‐to‐severe psoriasis , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  M. Entman,et al.  Critical Role of CXCL16 in Hypertensive Kidney Injury and Fibrosis , 2013, Hypertension.

[7]  M. Entman,et al.  CCR2 Regulates the Uptake of Bone Marrow-Derived Fibroblasts in Renal Fibrosis , 2013, PloS one.

[8]  Liqun He,et al.  Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. , 2013, Journal of the American Society of Nephrology : JASN.

[9]  R. Kalluri,et al.  Origin and function of myofibroblasts in kidney fibrosis , 2013, Nature Medicine.

[10]  K. Schmidbauer,et al.  Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. , 2013, Kidney international.

[11]  Zhaoyong Hu,et al.  Genetic deficiency of adiponectin protects against acute kidney injury , 2012, Kidney international.

[12]  Liqun He,et al.  Effect of Interleukin 6 Deficiency on Renal Interstitial Fibrosis , 2012, PloS one.

[13]  A. Duschl,et al.  STAT6-dependent and -independent mechanisms in Th2 polarization , 2012, European journal of immunology.

[14]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[15]  R. Colvin,et al.  Renal interstitial fibrosis: mechanisms and evaluation , 2012, Current opinion in nephrology and hypertension.

[16]  J. Malmström,et al.  Splicosomal and serine and arginine-rich splicing factors as targets for TGF-β , 2012, Fibrogenesis & tissue repair.

[17]  T. Kielian,et al.  Immunopathology and Infectious Diseases Central Nervous System Fibrosis Is Associated with Fibrocyte-Like Infiltrates , 2011 .

[18]  Liqun He,et al.  CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. , 2011, Journal of the American Society of Nephrology : JASN.

[19]  S. Yamasaki,et al.  Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production , 2011, BMC Immunology.

[20]  Yoshiya Tanaka,et al.  Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2011, Arthritis care & research.

[21]  V. Nizet,et al.  Fibrocyte-like cells recruited to the spleen support innate and adaptive immune responses to acute injury or infection , 2011, Journal of Molecular Medicine.

[22]  M. Kaplan,et al.  Transcriptional regulation by STAT6 , 2011, Immunologic research.

[23]  M. Entman,et al.  Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. , 2011, Journal of molecular and cellular cardiology.

[24]  Luke Barron,et al.  Macrophages: Master Regulators of Inflammation and Fibrosis , 2010, Seminars in liver disease.

[25]  R. Bucala,et al.  Fibrocytes in health and disease. , 2010, Experimental hematology.

[26]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[27]  K. Schmidbauer,et al.  CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes , 2009, Proceedings of the National Academy of Sciences.

[28]  R. Gomer,et al.  Identification of Markers that Distinguish Monocyte-Derived Fibrocytes from Monocytes, Macrophages, and Fibroblasts , 2009, PloS one.

[29]  Jae-Bong Park,et al.  IL-4 stimulates mouse macrophages to express APRIL through p38MAPK and two different downstream molecules, CREB and Stat6. , 2009, Cytokine.

[30]  S. Khoury,et al.  A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis , 2009, Journal of Neuroimmunology.

[31]  R. Gomer,et al.  Pivotal Advance: Th‐1 cytokines inhibit, and Th‐2 cytokines promote fibrocyte differentiation , 2008, Journal of leukocyte biology.

[32]  S. Kaneko,et al.  Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis , 2006, Proceedings of the National Academy of Sciences.

[33]  S. Akira,et al.  STAT6 deficiency inhibits tubulointerstitial fibrosis in obstructive nephropathy. , 2005, International journal of molecular medicine.

[34]  Biao Hu,et al.  Regulation of Found in Inflammatory Zone 1 Expression in Bleomycin-Induced Lung Fibrosis: Role of IL-4/IL-13 and Mediation via STAT-61 , 2004, The Journal of Immunology.

[35]  T. Wynn Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[36]  M. Säemann,et al.  Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor , 2004, European Surgery.

[37]  E. Neilson,et al.  Mechanisms of tubulointerstitial fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.

[38]  T. Wynn Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[39]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  Takashi Tanaka,et al.  The biology of Stat4 and Stat6 , 2000, Oncogene.

[41]  F. Jirik,et al.  A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. , 1999, Cellular immunology.

[42]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[43]  U. Schindler,et al.  Requirements for interleukin-4-induced gene expression and functional characterization of Stat6 , 1996, Molecular and cellular biology.

[44]  L. Truong,et al.  Cell apoptosis and proliferation in experimental chronic obstructive uropathy. , 1996, Kidney international.

[45]  W. Paul,et al.  Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene , 1996, Nature.

[46]  M. Kaplan,et al.  Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. , 1996, Immunity.

[47]  K. Nath,et al.  Tubulointerstitial changes as a major determinant in the progression of renal damage. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  T. Haverty,et al.  Mechanisms of tubulointerstitial fibrosis , 2004, Current opinion in nephrology and hypertension.